Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University Hospital, Bordeaux
With
Celgene
Age
18–55
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female;
Age 18-55 years;
Native French speaking;
Definite diagnosis of Relapsing-remitting MS (RRMS) according to McDonald 2017 criteria;
Disease duration\> 12 months and ≤ 15 years;
Computerized-Screening Cognitive Test (CSCT) score ≤ - 1.282 Standard Deviations (SD) (10th percentile) and/or cognitive complaint;
3 scores -1 SDa or 2 scores -1.5 SDb at least 2 of 5 baseline preselection neuropsychological battery tests in one of the following domains: processing speed or attention or working memory (SDMT, subtests alert, divided attention, visual scanning for selective attention, TAP and subtest working memory of the WAIS IV) and SDMT score not ≤ -3 SD;
Able to use a computer with Windows operating system, an internet connection;
Being affiliated to health insurance
Having signed an informed consent (at the latest on the day of inclusion and before any examination required by research)
You may not be if
Previous history of other neurological disease;
Psychiatric comorbidity including severe depression according to Diagnostic and Statistical Manual-IV (DSM-IV);
Current dependence on alcohol or other addiction to toxic;
Disabling visual or motor problems preventing participation to neuropsychological assessments;
Change of psychotropic drug or disease-modifying therapies since less than one month;
MS relapse in the month preceding the inclusion visit
Illiteracy, ie: unable to count or to read;
Acquisition disorders: dyslexia, dysphasia, dyscalculia and dyspraxia;
Pregnant or breastfeeding women;
Patient concerned by articles L 1121-5 to L 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent).
Clareo Health | Telerehabilitation of Multidomain Cognitive Impairment in Multiple Sclerosis
